Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician

Saved in:

Bibliographic Details
Published in:	Journal of cardiothoracic and vascular anesthesia Vol. 30; no. 3; pp. 823 - 830
Main Authors:	Lohrmann, Graham M., MD, Atwal, Danish, MD, Augoustides, John G., MD, FASE, FAHA, Askar, Wajih, MD, Patel, Prakash A., MD, Ghadimi, Kamrouz, MD, Makar, Gerges, MD, Gutsche, Jacob T., MD, Shamoun, Fadi E., MD, Ramakrishna, Harish, MD, FASE FACC
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-06-2016
Subjects:	activated charcoal Administration, Oral andexanet Anesthesia & Perioperative Care Antibodies, Monoclonal, Humanized - pharmacology Anticoagulants - pharmacology apixaban Arginine - analogs & derivatives Arginine - pharmacology aripazine atrial fibrillation Blood Coagulation Factors - pharmacology Critical Care dabigatran direct thrombin inhibitor edoxaban Factor VIIa - pharmacology factor Xa Factor Xa - pharmacology Factor Xa Inhibitors - pharmacology Humans idarucizumab novel oral anticoagulants Piperazines - pharmacology prothrombin complex concentrates recombinant factor VIIa Recombinant Proteins - pharmacology Renal Dialysis rivaroxaban vitamin K antagonists warfarin vitamin K antagonists activated charcoal andexanet idarucizumab rivaroxaban recombinant factor VIIa apixaban edoxaban prothrombin complex concentrates novel oral anticoagulants warfarin direct thrombin inhibitor atrial fibrillation dabigatran factor Xa aripazine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1053-0770 1532-8422
DOI:	10.1053/j.jvca.2016.01.005